Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Clinical trial NCT05688215 · RECRUITING

Trial details

NCT number: NCT05688215
Sponsor: Jonsson Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Borderline Resectable Pancreatic Adenocarcinoma Locally Advanced Pancreatic Ductal Adenocarcinoma

Start date: 2023-03-07
Primary completion: 2026-12-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.